BSPK Research | Milton Maxwell

BSPK

Bespoke Extracts, Inc.

0.2000

+0.0000+0%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap

2.25M

P/E (TTM)

Basic EPS (TTM)

-0.07

Dividend Yield

Recent Filings

8-K

Record Q3 revenue, margins up

11/19/25Nov 19, 2025

Bespoke Extracts crushed Q3 2025 with record $467,945 revenue, up 68.6% year-over-year, and 50.0% gross margins amid Colorado's shrinking cannabis market. Net loss shrank 72% to $78,088 as production soared 81% to 209,600 pre-rolls. Q4 outlook projects $425,000-$500,000 revenue. Operational excellence shines.

10-Q

Q3 FY2025 results

11/12/25Nov 12, 2025

Bespoke Extracts posted Q3 sales of $467.9K, up 68.6% y/y from $277.5K, with gross profit doubling to $234.2K as efficiencies trimmed COGS to 50.0% of revenue. Operating loss narrowed to $53.9K from $262.5K y/y, thanks to SG&A dropping 28.0% to $260.2K on lower stock comp; net loss hit $78.1K or $0.01/share versus $275.6K or $0.03 last year, with interest adding the gap. YTD sales climbed 37.4% to $1.12M, losses halved to $543.7K or $0.05/share. Cash dipped to $16.7K amid $123.6K operating burn, offset by $80K financing; payables swelled to $1.39M while secured debt nets $335.2K at 15%. Revenue hinges on Colorado dispensaries. Litigation lingers.

8-K

Note maturity extended to 2027

10/8/25Oct 8, 2025

Bespoke Extracts extended its $849,500 senior note's maturity from June 30, 2026, to June 30, 2027, via amendment with Infinity Management on October 8, 2025—its second pushback after November 2024. Principal, interest, and payments stay unchanged. Lenders get two more years. No other terms shift.

10-Q

Q2 FY2025 results

8/27/25Aug 27, 2025

Bespoke Extracts posted Q2 sales of $390.6k, up 40% y/y from $278.2k yet flat q/q as YTD revenue hit $653.7k (21% y/y gain); gross profit doubled to $197.5k on tighter costs, narrowing operating loss to $162k (35% better y/y) while net loss eased to $205k or $0.02/share from $261k or $0.03/share, confirmed vs 11.2M diluted shares. SG&A held steady but stock comp vanished; interest jumped on new secured notes. Cash dwindled to $1.4k amid $104k operating drain, offset by $45k financing, atop $2.8M liabilities including $849k CEO note and $299k secured debt. Vendor suit over $35.6k reserved fully. Single segment: Colorado dispensaries. Ongoing litigation risks loom.

8-K

Q1 revenue up 1%; rebrand success

7/7/25Jul 7, 2025

Bespoke Extracts rebranded to The Joint Company in Q1 2025, posting revenue of $263,159, up 1.0% from Q1 2024 despite an 8.8% Colorado cannabis market contraction. Gross profit climbed to $110,779 on production efficiencies; net loss shrank to $260,521. New products Doobskis and Dutch Blunts gained traction. Projects Q2 revenue over $385,000.

About

Bespoke Extracts, Inc., together with its subsidiary, Bespoke Extracts Colorado, LLC, produces and sells pre-rolled marijuana cigarettes in the United States. The company owns, manufactures, and distributes a diverse portfolio of cannabis consumer packaged goods under the Fresh Joints, Doobskis, DutchBlunts, and Wee Joints brand names. It also operates a facility dedicated to the production of marijuana-infused products, serving licensed marijuana dispensaries. The company was formerly known as DiMi Telematics International, Inc. and changed its name to Bespoke Extracts, Inc. in March 2017. Bespoke Extracts, Inc. was founded in 1988 and is headquartered in Aurora, Colorado.

CEO

Mr. Michael R. Feinsod J.D.

IPO

2/4/2008

Website

https://bespokeextracts.com

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic